Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Tuesday, May 23, 2017

Virtual reality stroke rehab platform gets FDA clearance

I bet it will take decades before this gets to your hospital. Your hospital probably has NO person or group whose sole function is to identify research that should be implemented into common practice to help stroke survivors get to 100% recovery. If that goal isn't for your doctor and stroke hospital, you have complete fucking incompetency there.
https://pharmaphorum.com/news/vr-stroke-rehab-fda-clearance/
MindMaze, a Swiss neurogaming company, has received FDA clearance for its virtual reality rehab platform for stroke and traumatic injury patients.
The MindMotion Pro platform features both motion capture technology and virtual 3D environments to help stroke patients regain the use of affected upper-body limbs.
Patients are presented with a scenario that challenges them to perform simple functions such as pointing, reaching or grasping using a virtual representation of their non-functional limb.
This virtual limb is controlled using the functional limb, for example, a patient who has lost the use of their left arm will use their right arm to complete each scenario. This method can kickstart the recovery of the non-functional limb’s capabilities.
The platform is given to stroke patients as a rehabilitation programme as early as one to six weeks post-stroke.
According to the company, beginning the therapy early can dramatically improve a patient’s recovery time as well as reduce losses in economic activity resulting from the condition – a number that currently sits at around $65 billion based on the approximately 800,000 US citizens that experience a stroke every year.
“Our work at the forefront of neuroscience and virtual reality allows patients to recover faster and return more fully to the life they lived before injury,” explained Dr. Tej Tadi, CEO and founder of MindMaze. “Over the last decade, we’ve honed this therapy to be cost-effective for both patients and healthcare providers.”
Alongside its newly FDA-cleared MindMotion Pro, the company has also completed 261 patient trials for its MindMotion Go.
MindMotion Go is designed as a portable version of MindMotion Pro, acting as either an outpatient equivalent or a continuation of the same rehabilitation care at home.
Results from a total patient population of 250 from therapy centre trials across the UK, Italy, Germany and Switzerland, MindMotion Go led to an increased patient engagement and adherence to therapy.
MindMotion Go is yet to receive FDA clearance.
Since its founding in 2012, MindMaze has accrued $108.5 million in funding, $100 million of which it obtained in February.

No comments:

Post a Comment